Dementia is characterized by the impairment of cognition and behavior of people over 65
years. Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder in the …

Acetylcholinesterase (AChE) enzyme inhibition is an important target for the management of
Alzheimer disease (AD) and AChE inhibitors are the main stay drugs for its management …

Acetylcholinesterase is involved in the termination of impulse transmission by rapid
hydrolysis of the neurotransmitter acetylcholine in numerous cholinergic pathways in the …

Human acetylcholinesterase (AChE) is a significant target for therapeutic drugs. Here we
present high resolution crystal structures of human AChE, alone and in complexes with drug …

The actions of many drugs involve enzyme inhibition. This is exemplified by the inhibitors of
monoamine oxidases (MAO) and the cholinsterases (ChE) that have been used for several …

Both Alzheimer's disease (AD) and Type 2 diabetes mellitus (T2DM) share the presence of
systemic and neuro-inflammation, enhanced production and accumulation of β-amyloid …

Background. Cholinesterases are a group of serine hydrolases that split the neurotransmitter
acetylcholine (ACh) and terminate its action. Of the two types, butyrylcholinesterase and …

The synaptic enzyme acetylcholinesterase (AChE) terminates transmission at cholinergic
synapses by rapidly hydrolysing acetylcholine. It is anchored within the synaptic cleft by a …

Objectives The inhibition of acetylcholinesterase (AChE), the key enzyme in the breakdown
of acetylcholine, is currently the main pharmacological strategy available for Alzheimer's …

In recent years, the investigation of acetylcholinesterase (AChE) inhibitors has gained
further interest, because the involvement of the peripheral site of the enzyme in the β …